AF
PRLD icon

Amalgamated Financial’s Prelude Therapeutics PRLD Stock Holding History

Amalgamated Financial’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$12K Buy
+1,764
New +$16.1K ﹤0.01% 2862

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Amalgamated Financial's PRLD Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Prelude Therapeutics (PRLD) in Q1 2022: 1,764 shares worth $12K. The stake represents ﹤0.01% of the portfolio and ranks #2862 among its holdings.

68 funds tracked by Wall St. Rank hold PRLD as of Q1 2022.

  • Amalgamated Financial held 1,764 shares of Prelude Therapeutics worth $12K as of Q1 2022.
  • Prelude Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Prelude Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2862 holding.
  • 68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.